6月19日，据CDE官网消息，漳州片仔癀药业股份有限公司联合申请药品“PZH2113 胶囊”，获得临床试验默示许可，受理号CXHL2400371。
公示信息显示，药品“PZH2113 胶囊”适应症：本品拟用于以弥漫性大B细胞淋巴瘤为主的复发性/难治性非霍奇金淋巴瘤的治疗。
漳州片仔癀药业股份有限公司药品申请临床试验默示许可获受理
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.